Morgan Stanley downgraded shares of Hikma Pharmaceuticals Plc (LON:HIK) to an equal weight rating in a research report report published on Monday, August 21st. The firm currently has GBX 1,350 ($17.44) price objective on the stock, down from their previous price objective of GBX 1,600 ($20.66).
Several other brokerages have also recently issued reports on HIK. HSBC Holdings plc reissued a reduce rating and issued a GBX 1,800 ($23.25) target price on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 5th. Numis Securities Ltd reissued a buy rating and issued a GBX 2,350 ($30.35) target price on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, May 11th. J P Morgan Chase & Co dropped their target price on Hikma Pharmaceuticals Plc from GBX 2,400 ($31.00) to GBX 1,800 ($23.25) and set a neutral rating on the stock in a research report on Friday, May 12th. Jefferies Group LLC cut Hikma Pharmaceuticals Plc to an underperform rating and dropped their target price for the stock from GBX 2,162 ($27.92) to GBX 1,450 ($18.73) in a research report on Wednesday, May 17th. Finally, Citigroup Inc. reaffirmed a neutral rating and set a GBX 1,550 ($20.02) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals Plc presently has a consensus rating of Hold and an average target price of GBX 1,574.18 ($20.33).
Shares of Hikma Pharmaceuticals Plc (LON HIK) traded down 0.17% on Monday, reaching GBX 1188.00. 746,556 shares of the company traded hands. Hikma Pharmaceuticals Plc has a one year low of GBX 1,101.00 and a one year high of GBX 2,346.00. The company’s market capitalization is GBX 2.85 billion. The firm has a 50-day moving average price of GBX 1,313.24 and a 200 day moving average price of GBX 1,689.79.
TRADEMARK VIOLATION NOTICE: “Hikma Pharmaceuticals Plc (LON:HIK) Downgraded to Equal weight at Morgan Stanley” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/hikma-pharmaceuticals-plc-hik-stock-rating-lowered-by-morgan-stanley/1533106.html.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with our FREE daily email newsletter.